Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Roy Vitkon"'
Autor:
Roi Gat, Miri Neeman, Shai Levi, Mor Levi, Nili Eilati, Yotam Bronstein, Tamir Shragai, Tsipora Neuman, Yafit Segman, Roy Vitkon, Moshe Mittelman, Irit Avivi, Yakir Moshe
Publikováno v:
HemaSphere, Vol 7, p e4811210 (2023)
Externí odkaz:
https://doaj.org/article/2d6ebc19a67847c1b107f6f5ad7269da
Autor:
Yakir Moshe, Shai Levi, Miri Neeman, Roi Gat, Mor Levi, Nili Eilati, Tamir Shragai, May Basood, Yafit Segman, Yaeli Baron, Efrat Luttwak, Tsipora Neuman, Roy Vitkon, Moshe Mittelman, Irit Avivi
Publikováno v:
HemaSphere, Vol 7, p e75498e6 (2023)
Externí odkaz:
https://doaj.org/article/ab4d16c1f22643a98c1d82c0ee9c63b8
Publikováno v:
HemaSphere, Vol 7, p e02697ff (2023)
Externí odkaz:
https://doaj.org/article/ca3400cccf934e9087abd0a0be5655b9
Autor:
Roy Vitkon, Dan Netanely, Shai Levi, Tomer Ziv-Baran, Ronit Ben-Yzak, Ben-Zion Katz, Noam Benyamini, Svetlana Trestman, Moshe Mittelman, Yael Cohen, Irit Avivi
Publikováno v:
Therapeutic Advances in Hematology, Vol 12 (2021)
Background: Daratumumab (Dara) is generally well tolerated, but is associated with increased risk of infection. Methods: We investigated hypogammaglobinemia occurrence in different Dara-based regimens. Multiple myeloma (MM) patients were treated with
Externí odkaz:
https://doaj.org/article/dd8de47cc8b34c739af4fc1aec55c49c
Autor:
Yotam Bronstein, Roi Gat, Shai Levi, Yael C. Cohen, Efrat Luttwak, Noam Benyamini, Tamir Shragai, Roy Vitkon, Miriam Neaman, Nili Eilaty, Mor Levi, Svetlana Trestman, Chava Perry, Yair Herishanu, Irit Avivi
Publikováno v:
Cancer cell. 40(6)
Autor:
Or Atar, Ron Ram, Irit Avivi, Odelia Amit, Roy Vitkon, Efrat Luttwak, Yael Bar-On, Yori Gidron
Publikováno v:
Journal of Clinical Medicine
Volume 12
Issue 3
Pages: 908
Volume 12
Issue 3
Pages: 908
This study examined the prognostic role of vagal nerve activity in patients with relapsed/refractory diffused large B-cell lymphoma (R/R-DLBCL) treated with chimeric antigen receptor cell therapy (CAR-T) and in patients with multiple myeloma (MM) und
Autor:
Dan Netanely, Ben-Zion Katz, Ronit Ben-Yzak, Irit Avivi, Shai Levi, Roy Vitkon, Svetlana Trestman, Moshe Mittelman, Yael C Cohen, Tomer Ziv-Baran, Noam Benyamini
Publikováno v:
Therapeutic Advances in Hematology, Vol 12 (2021)
Therapeutic Advances in Hematology
Therapeutic Advances in Hematology
Background: Daratumumab (Dara) is generally well tolerated, but is associated with increased risk of infection. Methods: We investigated hypogammaglobinemia occurrence in different Dara-based regimens. Multiple myeloma (MM) patients were treated with
Autor:
Adir Shaulov, Yael C Cohen, Noa Lavi, Moshe E. Gatt, Irit Avivi, Tamar Tadmor, Roy Vitkon, Hila Magen, Nethanel Horowitz, Evgeni Chubar, Svetlana Trestman, Ory Rouvio, Olga Shvetz, Tomer Ziv-Baran, Natalia Kreiniz
Publikováno v:
Annals of hematology. 99(6)
Ixazomib, the first oral proteasome inhibitor (PI), has been approved for the treatment of relapsed refractory multiple myeloma (RRMM) in combination with lenalidomide and dexamethasone, based on the TOURMALINE-MM1 phase 3 trial, which demonstrated t
Autor:
Roy Vitkon, Natalia Kreiniz, Irit Avivi, Yael C Cohen, Hila Magen, Tamar Tadmor, Adir Shaulov, Moshe E. Gatt, Noa Lavi, Evgeni Chubar, Svetlana Trestman, Ory Rouvio, Olga Shvetz
Publikováno v:
Blood. 132:1972-1972
Introduction Ixazomib is an orally available proteasome inhibitor, shown to be safe and efficacious in combination with lenalidomide and dexamethasone (IRd regimen) in patients with relapsed and refractory multiple myeloma (RRMM) with 1-3 prior lines